JNJ

233.01

+1.03%↑

UNH

284.01

-0.6%↓

TMO

568.43

-2.07%↓

ABT

108.96

-0.46%↓

ISRG

478.71

-3.54%↓

JNJ

233.01

+1.03%↑

UNH

284.01

-0.6%↓

TMO

568.43

-2.07%↓

ABT

108.96

-0.46%↓

ISRG

478.71

-3.54%↓

JNJ

233.01

+1.03%↑

UNH

284.01

-0.6%↓

TMO

568.43

-2.07%↓

ABT

108.96

-0.46%↓

ISRG

478.71

-3.54%↓

JNJ

233.01

+1.03%↑

UNH

284.01

-0.6%↓

TMO

568.43

-2.07%↓

ABT

108.96

-0.46%↓

ISRG

478.71

-3.54%↓

JNJ

233.01

+1.03%↑

UNH

284.01

-0.6%↓

TMO

568.43

-2.07%↓

ABT

108.96

-0.46%↓

ISRG

478.71

-3.54%↓

Home・Aandelen Lijst・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Gesloten

SectorGezondheidszorg

25.13 2.36

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

24.55

Max

25.51

Belangrijke statistieken
By Trading Economics
Inkomsten	-10M -67M
Winstmarge	-7,753.425
Werknemers	186
EBITDA	-9.8M -73M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+116.95% upside

Dividenden
By Dow Jones
Volgende Winsten	25 feb 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	260M 1.8B
Vorige openingsprijs	22.77
Vorige sluitingsprijs	25.13

Nieuwssentiment

By Acuity

50%

152 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

18.91 / 20.63 Steun & Weerstand

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 feb 2026, 23:11 UTC

Belangrijke Marktbewegers

Acquisities, Fusies, Overnames

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3 feb 2026, 23:50 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

3 feb 2026, 23:50 UTC

Marktinformatie

Nikkei May Decline After Hitting All-Time High -- Market Talk

3 feb 2026, 23:42 UTC

Marktinformatie

Gold Edges Lower on Possible Technical Correction -- Market Talk

3 feb 2026, 23:41 UTC

Acquisities, Fusies, Overnames

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3 feb 2026, 23:38 UTC

Winsten

AMD Sales Climb on Help From Data-Center Business -- Update

3 feb 2026, 23:29 UTC

Acquisities, Fusies, Overnames

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3 feb 2026, 23:27 UTC

Acquisities, Fusies, Overnames

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3 feb 2026, 23:25 UTC

Acquisities, Fusies, Overnames

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3 feb 2026, 23:23 UTC

Acquisities, Fusies, Overnames

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3 feb 2026, 23:22 UTC

Acquisities, Fusies, Overnames

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3 feb 2026, 23:19 UTC

Marktinformatie

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3 feb 2026, 23:19 UTC

Marktinformatie

Global Equities Roundup: Market Talk

3 feb 2026, 22:56 UTC

Belangrijke Marktbewegers

Acquisities, Fusies, Overnames

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3 feb 2026, 22:40 UTC

Winsten

Amdocs Extends Collaboration With T-Mobile

3 feb 2026, 22:39 UTC

Winsten

Amdocs 1Q Adj EPS $1.81

3 feb 2026, 22:39 UTC

Winsten

Amdocs 1Q Rev $1.16B

3 feb 2026, 22:39 UTC

Winsten

Amdocs 1Q EPS $1.45 >

3 feb 2026, 22:38 UTC

Winsten

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3 feb 2026, 22:30 UTC

Acquisities, Fusies, Overnames

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3 feb 2026, 22:22 UTC

Acquisities, Fusies, Overnames

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3 feb 2026, 22:14 UTC

Winsten

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3 feb 2026, 22:13 UTC

Winsten

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3 feb 2026, 22:12 UTC

Winsten

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3 feb 2026, 22:10 UTC

Winsten

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3 feb 2026, 22:10 UTC

Winsten

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3 feb 2026, 22:10 UTC

Marktinformatie

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3 feb 2026, 22:10 UTC

Winsten

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3 feb 2026, 22:09 UTC

Winsten

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3 feb 2026, 22:09 UTC

Winsten

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

116.95% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 53.5 USD 116.95%

Hoogste 90 USD

Laagste 24 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Celldex Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

152 / 352 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.